Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Criteria for disease activity in Wegener's granulomatosis: a requirement for longitudinal clinical studies.

× No keyword cloud information.

6 in total

Review 1. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

Authors: Bernhard Hellmich; Oliver Flossmann; Wolfgang L Gross; Paul Bacon; Jan Willem Cohen-Tervaert; Loic Guillevin; David Jayne; Alfred Mahr; Peter A Merkel; Heiner Raspe; David G I Scott; James Witter; Hasan Yazici; Raashid A Luqmani
Journal: Ann Rheum Dis Date: 2006-12-14 Impact factor: 19.103

Review 2. Development of comprehensive disease assessment in systemic vasculitis.

Authors: Oliver Flossmann; Paul Bacon; Kirsten de Groot; David Jayne; Niels Rasmussen; Philip Seo; Kerstin Westman; Raashid Luqmani
Journal: Ann Rheum Dis Date: 2006-05-25 Impact factor: 19.103

Review 3. Assessment of disease activity in systemic vasculitis.

Authors: W Y Tse; P Cockwell; C O Savage
Journal: Postgrad Med J Date: 1998-01 Impact factor: 2.401

4. Serum markers of T cell activation in relapses of Wegener's granulomatosis.

Authors: C A Stegeman; J W Tervaert; M G Huitema; C G Kallenberg
Journal: Clin Exp Immunol Date: 1993-03 Impact factor: 4.330

5. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis: a predominant role for the IgG3 subclass of ANCA.

Authors: A H Mulder; C A Stegeman; C G Kallenberg
Journal: Clin Exp Immunol Date: 1995-08 Impact factor: 4.330

6. Relevance of classic anti-neutrophil cytoplasmic autoantibody (C-ANCA)-mediated inhibition of proteinase 3-alpha 1-antitrypsin complexation to disease activity in Wegener's granulomatosis.

Authors: K M Dolman; C A Stegeman; B A van de Wiel; C E Hack; A E von dem Borne; C G Kallenberg; R Goldschmeding
Journal: Clin Exp Immunol Date: 1993-09 Impact factor: 4.330

6 in total